Stock Analysts’ Updated EPS Estimates for November 18th (BBWI, BKNG, CABA, CRWD, FATE, GAP, MGTX, NFLX, OCGN, ROST)

Stock Analysts’ updated eps estimates for Monday, November 18th:

Bath & Body Works (NYSE:BBWI) had its outperform rating reissued by analysts at Telsey Advisory Group. Telsey Advisory Group currently has a $42.00 target price on the stock.

Booking (NASDAQ:BKNG) had its target price increased by Tigress Financial from $4,580.00 to $5,600.00. They currently have a strong-buy rating on the stock.

Cabaletta Bio (NASDAQ:CABA) had its outperform rating reaffirmed by analysts at William Blair.

CICC Research assumed coverage on shares of CrowdStrike (NASDAQ:CRWD). The firm issued a market perform rating and a $295.00 price target on the stock.

Fate Therapeutics (NASDAQ:FATE) was upgraded by analysts at Bank of America Co. from an underperform rating to a neutral rating.

GAP (NYSE:GAP) had its market perform rating reaffirmed by analysts at Telsey Advisory Group. The firm currently has a $26.00 target price on the stock.

MeiraGTx (NASDAQ:MGTX) had its buy rating reissued by analysts at Chardan Capital. The firm currently has a $36.00 target price on the stock.

Netflix (NASDAQ:NFLX) had its outperform rating reaffirmed by analysts at Wedbush. They currently have a $950.00 price target on the stock, up from their previous price target of $800.00.

Ocugen (NASDAQ:OCGN) had its buy rating reiterated by analysts at Chardan Capital. The firm currently has a $6.00 target price on the stock.

Ross Stores (NASDAQ:ROST) had its market perform rating reaffirmed by analysts at Telsey Advisory Group. Telsey Advisory Group currently has a $175.00 price target on the stock.

SpringWorks Therapeutics (NASDAQ:SWTX) had its outperform rating reaffirmed by analysts at Wedbush. Wedbush currently has a $77.00 price target on the stock.

Waldencast (NASDAQ:WALD) had its outperform rating reiterated by analysts at Telsey Advisory Group. The firm currently has a $6.00 price target on the stock.

WD-40 (NASDAQ:WDFC) had its buy rating reissued by analysts at DA Davidson. DA Davidson currently has a $322.00 price target on the stock.